The impact of rotigotine on cardiovascular autonomic function in early parkinson's disease

Camilla Rocchi, Mariangela Pierantozzi, Valerio Pisani, Girolama Alessandra Marfia, Alessandra Di Giorgio, Paolo Stanzione, Giorgio Bernardi, Alessandro Stefani

Research output: Contribution to journalArticlepeer-review


Dysautonomia can occur in early stages of Parkinson's disease (PD) influencing tolerance to dopaminergic therapies. Rotigotine, a non-ergot dopamine agonist, has recently been developed as an effective alternative antiparkinsonian drug, but its influence on the autonomic nervous system was not investigated. Twenty subjects out of 34 consecutive de novo PD patients were submitted to full assessment of cardiovascular autonomic function before and after reaching a stable rotigotine regimen [6 mg/24 h (n = 3) or 8 mg/24 h (n = 17)]. Patients reached significant clinical improvement (-27% on the Unified Parkinson's Disease Rating Scale part III) and did not show significant differences in cardiovascular tests compared to baseline data. However, an unexpected trend towards increasing systolic blood pressure after head-up tilt test was detected. Our study demonstrates that rotigotine does not influence cardiovascular autonomic responses in early de novo PD patients. Consequently, it may represent a well-tolerated and efficacious therapeutic option in newly diagnosed PD subjects.

Original languageEnglish
Pages (from-to)187-192
Number of pages6
JournalEuropean Neurology
Issue number3
Publication statusPublished - Sep 2012


  • Autonomic function tests
  • Dopamine agonists
  • Orthostatic hypotension
  • Parkinson's disease
  • Rotigotine

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology


Dive into the research topics of 'The impact of rotigotine on cardiovascular autonomic function in early parkinson's disease'. Together they form a unique fingerprint.

Cite this